Hologic, Inc. (NASDAQ:HOLX) Shares Purchased by CIBC Asset Management Inc

CIBC Asset Management Inc increased its position in shares of Hologic, Inc. (NASDAQ:HOLXGet Rating) by 196.3% during the first quarter, Holdings Channel.com reports. The fund owned 71,148 shares of the medical equipment provider’s stock after acquiring an additional 47,134 shares during the quarter. CIBC Asset Management Inc’s holdings in Hologic were worth $5,466,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of HOLX. Fieldpoint Private Securities LLC increased its stake in Hologic by 61.4% in the 1st quarter. Fieldpoint Private Securities LLC now owns 334 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 127 shares in the last quarter. Hudock Inc. increased its stake in Hologic by 1,825.0% in the 1st quarter. Hudock Inc. now owns 385 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 365 shares in the last quarter. FinTrust Capital Advisors LLC purchased a new position in Hologic in the 1st quarter worth about $45,000. Quent Capital LLC purchased a new position in Hologic in the 4th quarter worth about $51,000. Finally, Rosenberg Matthew Hamilton purchased a new position in Hologic in the 1st quarter worth about $55,000. 92.70% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Hologic

In other Hologic news, insider Jan Verstreken sold 6,500 shares of the business’s stock in a transaction on Tuesday, May 17th. The stock was sold at an average price of $78.80, for a total value of $512,200.00. Following the transaction, the insider now owns 64,191 shares of the company’s stock, valued at $5,058,250.80. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 1.54% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have commented on HOLX. SVB Leerink raised their price objective on Hologic to $85.00 and gave the stock an “outperform” rating in a research report on Tuesday, May 17th. Citigroup decreased their price objective on Hologic from $78.00 to $75.00 in a research report on Thursday, April 28th. Morgan Stanley decreased their price objective on Hologic from $72.00 to $70.00 and set an “equal weight” rating for the company in a research report on Thursday, July 28th. UBS Group began coverage on Hologic in a research report on Wednesday, July 20th. They set a “neutral” rating and a $73.00 price objective for the company. Finally, Wells Fargo & Company lowered Hologic from an “overweight” rating to an “equal weight” rating and decreased their price objective for the stock from $90.00 to $75.00 in a research report on Monday, April 25th. Seven research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $76.71.

Hologic Stock Up 0.3 %

HOLX opened at $71.40 on Friday. The business has a 50 day moving average price of $71.14 and a 200 day moving average price of $72.79. Hologic, Inc. has a twelve month low of $66.58 and a twelve month high of $81.04. The company has a debt-to-equity ratio of 0.57, a quick ratio of 3.32 and a current ratio of 3.91. The firm has a market cap of $17.83 billion, a P/E ratio of 12.04, a price-to-earnings-growth ratio of 0.81 and a beta of 1.05.

Hologic (NASDAQ:HOLXGet Rating) last issued its quarterly earnings results on Wednesday, July 27th. The medical equipment provider reported $0.95 EPS for the quarter, topping the consensus estimate of $0.69 by $0.26. The company had revenue of $1 billion for the quarter, compared to the consensus estimate of $896.71 million. Hologic had a return on equity of 37.48% and a net margin of 28.93%. The company’s revenue for the quarter was down 14.2% on a year-over-year basis. During the same period in the previous year, the business posted $1.33 EPS. Research analysts forecast that Hologic, Inc. will post 5.82 EPS for the current year.

About Hologic

(Get Rating)

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health.

See Also

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLXGet Rating).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.